Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03249584 · ClinicalTrials.gov registry record · NA
OsteoCool Tumor Ablation Post-Market Study
A NA study of Metastasis Spine and Metastasis to Bone, sponsored by MedtronicNeuro.
- Completed
- Registry status
- NA
- Development phase
- 218
- Enrollment target
- 16
- Study locations
NCT03249584 is a NA study of Metastasis Spine and Metastasis to Bone that has completed, run by MedtronicNeuro. The registered enrollment target is 218 participants. The trial reports 16 study locations across 11 states.
The verdict
NCT03249584, a NA study of Metastasis Spine and Metastasis to Bone, has completed, sponsored by MedtronicNeuro.
- COMPLETED
- Registry status
- NA
- Development phase
- 218 participants
- Enrollment target
- 16
- Study locations
Study Summary
This study evaluates the effectiveness of the Medtronic OsteoCool™ RF Ablation System.
Conditions Studied
Interventions
- DEVICE OsteoCool™ RF Ablation
Study Locations (16)
Other
- Sunnybrook Health Science Centre - Toronto
- Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil - Strasbourg
- Universitätsklinikum Leipzig AöR - Leipzig
- Centre Hospitalier de Luxembourg - Luxembourg
Georgia
- Emory University School of Medicine - Atlanta
- Northside Hospital - Cumming
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Duke University Medical Center - Durham
Arizona
- Banner - University Medical Center Phoenix - Phoenix
California
- Saint Jude Medical Center - Fullerton
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- University of Massachusetts Memorial Medical Center - Worcester
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2020-07-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03249584
The ClinicalTrials.gov registry entry for NCT03249584 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedtronicNeuro, which has 51 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastasis Spine appearing as the primary indexed condition, and to 1 intervention - of which OsteoCool™ RF Ablation is the first listed.
NCT03249584 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Other, Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03249584 about?
NCT03249584 is a clinical study titled "OsteoCool Tumor Ablation Post-Market Study". This study evaluates the effectiveness of the Medtronic OsteoCool™ RF Ablation System.
What is the current status of trial NCT03249584?
This trial is currently completed. It is a NA study. The enrollment target is 218 participants. The study started on 2017-10-12. Estimated completion is 2020-07-17.
What conditions does trial NCT03249584 study?
This clinical trial studies the following conditions: Metastasis Spine, Metastasis to Bone.
What interventions are being tested in trial NCT03249584?
The interventions under investigation include: OsteoCool™ RF Ablation (DEVICE).
Who is sponsoring clinical trial NCT03249584?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03249584 being conducted?
This trial has 16 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastasis Spine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.